Literature DB >> 23999611

The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.

William P Conners1, Abraham Morgentaler.   

Abstract

Testosterone deficiency (TD) is a common clinical condition that causes sexual and non-sexual symptoms. Low serum concentrations of testosterone also predict significant health outcomes, such as diabetes, metabolic syndrome, and increased mortality. Treatment with testosterone therapy (TTh) effectively improves symptoms, and also has a positive impact on body composition and bone density. Since there is no serum testosterone value that reliably identifies men who will respond to treatment from those who will not, healthcare providers must exercise clinical judgment in making the diagnosis of TD. Multiple formulations of TTh are available, each with advantages and disadvantages. Overall, TTh is relatively safe but the risks, such as erythrocytosis, makes long-term monitoring mandatory. The evidence does not support concerns regarding cardiovascular and prostate cancer risks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999611     DOI: 10.1007/s11934-013-0370-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  56 in total

1.  Identification of late-onset hypogonadism in middle-aged and elderly men.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi
Journal:  N Engl J Med       Date:  2010-06-16       Impact factor: 91.245

2.  Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.

Authors:  Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Circulation       Date:  2007-11-26       Impact factor: 29.690

3.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.

Authors:  Andrew R McCullough; Mohit Khera; Irwin Goldstein; Wayne J G Hellstrom; Abraham Morgentaler; Laurence A Levine
Journal:  J Sex Med       Date:  2012-01-12       Impact factor: 3.802

5.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-11       Impact factor: 6.053

6.  Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study.

Authors:  Bu B Yeap; S A Paul Chubb; Zoë Hyde; Konrad Jamrozik; Graeme J Hankey; Leon Flicker; Paul E Norman
Journal:  Eur J Endocrinol       Date:  2009-08-06       Impact factor: 6.664

7.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.

Authors:  Chris J Malkin; Peter J Pugh; Richard D Jones; Dheeraj Kapoor; Kevin S Channer; T Hugh Jones
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

8.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe Casanueva; Gianni Forti; Aleksander Giwercman; Ilpo T Huhtaniemi; Krzysztof Kula; Margus Punab; Steven Boonen; Dirk Vanderschueren
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

9.  Trends in androgen prescribing in the United States, 2001 to 2011.

Authors:  Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

10.  Liver damage from long-term methyltestosterone.

Authors:  D Westaby; S J Ogle; F J Paradinas; J B Randell; I M Murray-Lyon
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

View more
  1 in total

1.  Barriers to receiving testosterone replacement therapy in the community during COVID-19 pandemic.

Authors:  Victoria L Troesch; Denise Juhr; Amy Pearlman
Journal:  Transl Androl Urol       Date:  2021-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.